a b s t r a c t SM5-1 is a humanized mouse monoclonal antibody, targeting an over-expressed membrane protein of approximately 230 kDa in hepatocellular carcinoma (HCC). SM5-1 can be used for target therapy in hepatocellular carinoma due to its ability of inhibiting cell growth and inducing apoptosis. However, the tumor inhibition efficacy of SM5-1 in HCC cancer treatment remains low. In this study, we synthesized SM5-1-conjugated gold nanoparticles (Au-SM5-1 NPs) and investigated their anticancer efficacy in HCC both in vitro and in vivo. The tumor inhibition rates of Au-SM5-1 NPs for subcutaneous tumor mice were 40.10% ± 4.34%, 31.37% ± 5.12%, and 30.63% ± 4.87% on day 12, 18, and 24 post-treatment as determined by bioluminescent intensity. In addition, we investigated the antitumor efficacy of Au-SM5-1 NPs in orthotopic HCC tumor models. The results showed that the inhibition rates of Au-SM5-1 NPs can reach up to 39.64% ± 4.87% on day 31 post-treatment determined by the bioluminescent intensity of the abdomen in tumor-bearing mice. Furthermore, three-dimensional reconstruction results of the orthotopic tumor revealed that Au-SM5-1 NPs significantly inhibited tumor growth compared with SM5-1 alone. Our results suggested that the developed Au-SM5-1 NPs has great potential as an antibodybased nano-drug for HCC therapy.
Introduction
Hepatocellular carcinoma (HCC) has become one of the most leading causes of cancer-related deaths worldwide [1, 2] . Although the treatment of HCC has been improved significantly, including surgery, chemotherapy, and radiation, the survival rates of HCC patients have not been substantially improved over the last decade [3, 4] . In recent years, tumor-targeted therapy and immunotherapy, including antibody therapy, T cell immunotherapy and macrophage cell immunotherapy, have been studied extensively [5e9]. Cetuximab, an anti-EGFR monoclonal antibody, in phase II studies, has been used for targeted therapy. But it has shown poor activity against HCC. Bevacizumab, an anti-VEGF monoclonal antibody, has been demonstrated efficacy to HCC. However, this efficacy is limited by high toxicity as bleeding and deep venous thrombosis, which may worsen the liver function in already cirrhotic patients [10] . GC33, a humanized antibody against Glypican-3 showed an inhibition effect on HCC cell proliferation both in vitro and in vivo [11] .
SM5-1 is a monoclonal antibody (mAb) that binds specifically to a 230-kDa membrane protein (p230) overexpressed in several types of cancers, including HCC, melanoma and breast cancer. Receptor protein p230 was originally discovered in melanoma and proved to be useful in the immunohistochemical evaluation of melanoma [12] . Reinke et al. studied the differential expression of receptor protein P230 in primary and metastatic melanoma [13] . SM5-1 has been proved to be able to inhibit tumor cell growth or induce apoptosis. Thus, SM5-1 has been used for diagnosis and targeted treatment of P230 overexpressing HCC cancer [14e17] . A subsequent relevant study indicated that the antitumor activity of SM5-1 is highly related to the expression level of the SM5-1 binding P230 in the HCC cells [18] . However, the antitumor efficiency of SM5-1 is still poor and needs to be improved urgently.
Antibody conjugated nanoparticle has been widely used for molecular imaging and enhancing targeted therapy of HCC [19e23] . Nanoparticles, especially gold nanoparticles (Au NPs), have been widely explored in biomedical imaging, drug delivery, diagnostic tests, and tumor treatment [24e26] . Previous studies have shown that Au NPs-conjugated antibodies can be used for increasing cytotoxicity and delivery efficacy in several cancer cells [27, 28] . Dechent's group studied the toxicity of Au NPs and demonstrated a relationship between size and their toxicity [29, 30] . Another exciting application of Au NPs is that they are used as radiation sensitizers to improve antitumor efficacy [31e33] .
In this study, we reported the conjugation of SM5-1 with Au NPs (Au-SM5-1) and studied its inhibitory effects through in vitro cell proliferation assays and in vivo animal treatment experiments with HCC-LM3-fLuc tumor models. Then, adaptive finite element method was applied for three-dimensional (3D) reconstruction in orthotopic HCC xenograft mouse model. Immunohistochemistry (IHC) experiments were also carried out to demonstrate the influence of Au-SM5-1 NPs, SM5-1, Au-IgG NPs, IgG and Au NPs on tumor cell proliferation, angiogenesis, and apoptosis. In addition, cell uptake experiments proved that enhanced clathrin-dependent endocytosis increased the concentration of Au-SM5-1 NPs. Simultaneously, gene expression profiles were investigated in the HCC-LM3-fLuc tumor cells by using gene-chip screening and verified the expression of key genes using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Materials and methods

Materials
Hydrate (HAuCl 4 $4H 2 O), sodium citrate, and sodium borohydride (NaBH 4 ) were obtained from SinoReagent, China. De-ionized water (DI water, 18.2 MU cm) from the Milli-Q Gradient system was used in all of the preparations. CellTiter96 ® AQueous One Solution
Cell Proliferation Assay (MTS, batch No. G358A) was purchased from Promega (Madison, WI, USA). Control IgG was purchased from YEASON (Shanghai, China).
Preparation of Au-SM5-1 NPs
First, citrate-stabilized Au NPs with an average diameter of about 2.6 nm were prepared as follows: HAuCl4 aqueous solution (1.0 ml, 1% w/v) was added into DI water (100 ml) with vigorous stirring for 1 min. Sodium citrate solution (1.0 ml, 1% w/v) was added to react for 1 min. NaBH4 (1.0 ml, 0.075% w/v) in sodium citrate (1% w/v) solution was added and continuously stirred for 5 min, and then stored at 4 C [34] . Then, thioglycolic acid was mixed with citrate-stabilized Au NPs for 12 h to obtain thioglycolic acid-stabilized Au NPs, and the unreacted portion of thioglycolic acid was removed using a dialysis method. The antibody SM5-1 was later connect to thioglycolic acid-stabilized Au NPs by the catalysis of EDC/NHS. Finally, the reaction solution was centrifuged at 14,000 rpm for 25 min, and the supernatant was discarded three times to obtain pure Au-SM5-1, the final product was dissolved in phosphate buffered saline (PBS) for further use. IgG is abbreviation of Immunoglobulin G which play an important role in the organic immunity such as antibiosis, antiviral, etc. and it is usually used as the contrast antibody in the immunotherapy research. Au-IgG NPs were prepared similarly.
Characterization of Au-SM5-1 NPs, Au NPs, and SM5-1
The size distribution and zeta potential of Au-SM5-1 NPs were examined using a 90Plus/BI-MAS DLS analyzer (Brookhaven Instruments, NY, USA) [35] . Each sample of Au-SM5-1 NPs was diluted to an appropriate concentration of 1.25 mg/ml with DI water. Six replicate samples of each type of vesicles were analyzed at a scatter angle of Q ¼ 90 and a wavelength of 660 nm at room temperature.
The amount of SM5-1-conjugated Au NPs was quantified by the Micro BCA method as described previously [36, 37] . Briefly, 500 ml Micro BCA working solution was added to 500 ml of PBS (pH 7.0), the dispersion of Au-SM5-1 (1 mg/ml) and Au NPs (1 mg/ml, served as blank), respectively. After a 60 min incubation period, the absorbance was measured at 560 nm using BIO-TEK EL Â 800 Universal Microplate Reader. The results were compared to a standard curve of SM5-1 solution in PBS (pH 7.0) ranging from 0.5 to 20 mg/ml. The number of antibodies that calculated by Micro BCA experiment were consistent with the results estimated from the SM5-1 conjugated reaction experiment. The morphologies of Au-SM5-1 NPs and Au NPs were measured by scanning electron microscopy (SEM, Hitachi S-4300; Hitachi, Tokyo, Japan) with accelerating voltage of 15 KV. TEM images of Au-SM5-1 and Au NPs were obtained using a Tecnai Spirit Microscope with a charge coupled device (CCD) camera operated at 80 KV.
Cell culture
HCC-LM3-fLuc, HepG2 human HCC cells and human normal liver cell line HL7702 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in a humidified incubator at 37 C in a 5% CO 2 atmosphere.
In vitro cell proliferation assay
HCC-LM3-fLuc cells (1 Â 10 4 ) were mixed with seven different concentrations (n ¼ 3) of Au NPs, SM5-1, IgG, Au-IgG NPs and Au-SM5-1 NPs for 24 h in five transparent 96-well plates. Then, cell viability was measured using a CellTiter 96 cell proliferation assay kit (MTS, Promega). Briefly, a 20 ml of MTS solution was added to each well. After incubation for 2 h at 37 C, the absorbance was measured at 570 nm using a BioTek Synergy HT Universal Microplate Reader. Additionally, seven concentrations (n ¼ 3) of Au-SM5-1 NPs were added into a black 96-well plate to incubate for 24 h.
The bioluminescent intensity was evaluated by adding 20 ml of luciferin to each well for 3 min at 37 C. The bioluminescent images were acquired using home-built bioluminescence imaging system [38e41]. another 3 h at 37 C. This treatment will lead to conjugation of one gold nanoparticle and three SM5-1 antibodies, detailed in Section 3.1. After incubation, 4 C PBS was added to terminate uptake and the cells were washed carefully with PBS (Â3) and digested to obtain cell suspension. The cells were collected and analyzed using flow cytometry analysis. Meanwhile, similar experiments were carried out and the cells were added Au NPs at a concentration of 2 nM. The cells treated with Au NPs were analyzed using inductively coupled plasma mass spectrometry (ICP-MS). All these experiments were performed for three times.
RNA extraction
HCC-LM3-fLuc cells were added into each well of a 6-well plate (6 Â 10 5 cells/well) and incubated with 1 ml of medium overnight.
The cells were then treated with Au NPs, SM5-1, and Au-SM5-1 NPs at SM5-1 concentration of 0.1 mg/ml (40 ml of Au-SM5-1, 9 ml of SM5-1, 31 ml of Au NPs, all drug concentrations were 0.1 mg/ml) and incubated for 72 h. Culture media and drugs were refreshed every 24 h, after that drugs at the abovementioned concentrations were added again into each well. The total RNA was extracted using the Trizol reagent (Invitrogen, USA) from drug-treated cells according to the manufacturer's protocol and was purified by the RNeasy mini kit (QIAGEN, No. 217004). The RNA of each sample was amplified and labeled following the manufacturer's protocols (http://www. affymetrix.com). RNA concentrations were measured with a ND-1000 spectrophotometer (NanoDrop Technologies), and the quality (RNA Integrity Number, RIN) was evaluated using the Agilent 2100 Bioanalyzer system (Agilent Biotechnologies) [42, 43] .
qRT-PCR
According to the GeneChip results, shown in Supplementary Information S.1, six complementary DNAs were selected to perform the following PCR experiments. qRT-PCR was carried out by ABI SYBR master mix (Applied Biosystems) with gene specific primers in a 20 ml of mixture following manufacturers' instructions on the ABI PRISM 7500 Detection System (Applied Biosystems). Triplicate reactions were done in three independent experiments. Expression data were normalized to the geometric mean of housekeeping gene b-actin to control the variability in expression levels, and they were analyzed using the 2 ÀDDCT method described by Livak and Schmittgen [44] . The gene specific primer pairs were designed and showed in Table 1 .
Flow cytometry analysis
Flow cytometry analysis was performed to define the cell cycle distribution for Au NPs-treated, Au-SM5-1-treated, SM5-1-treated, and untreated cells. Briefly, cells were harvested by trypsinization, washed with PBS, and resuspended in 75% ethanol at 4 C for at least 30 min. Cells (1e2 Â 10 6 ) were incubated for 30 min with a solution containing 50 mg/ml propidium iodide (Sigma), 1 mM EDTA, 0.1% Triton-X-100 and 100 mg/ml RNase A in PBS for 30 min at 37 C [45] . The suspension was passed through a nylon mesh filter and analyzed on a flow cytometer (FACscan: Becton Dickinson Immunocytometry Systems, San Jose, CA) as previously described [46, 47] .
In vivo antitumor studies for subcutaneous tumor models
Female BALB/c nude mice (5 weeks old) were purchased from the Department of Experimental Animals, Peking University Health Science Center. All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee at Peking University. All animal experiment protocols in this study have been approved by institutional board. 
Orthotopic tumor models and three-dimensional reconstruction of the interior liver tumor
The 18 orthotopic tumor models were established by injecting 2 Â 10 6 HCC-LM3-fLuc tumor cells into the liver of each BALB/c nude mouse. The mice were randomized and separated into 6 groups each consisting of 3 mice. One group (control) was injected i.v. with PBS. The other groups (treatment) were subjected to antitumor treatment via i.v. injection of Au-SM5-1 NPs, SM5-1 NPs, Au-IgG NPs, IgG and Au NPs on the 7th day in consideration of taking the same tumor growth time for the subcutaneous tumorbearing mice increased to about 50 mm 3 . The mice were treated with four doses given on days 0, 1, 2 and 3. The drug treatment was repeated for Au-SM5-1 NPs (High) group on days 12, 13, 14 and 15.
The antitumor efficacy was evaluated on day 0, 6, 12, 18, 24 and 30 by acquiring the bioluminescent images of the abdomen of the orthotopic liver cancer mice and calculated the bioluminescent intensity. Data acquisition and reconstruction methods were detailed in Supplementary Information S.5.
Immunohistochemical examination and analysis
In order to evaluate in vivo tumor proliferation, angiogenesis and apoptosis histologically, PBS-treated, Au NPs-treated, Au-SM5-1 NPs (low)-treated, Au-IgG NPs-treated, IgG-treated and SM5-1-treated tumors in triplicate (13 days post-treatment) were excised, fixed in formalin, embedded in paraffin and cut into 3-mm- [48] . In situ apoptosis assay was carried out with the Fluorescein FragEL DNA fragmentation Detection Kit (Calbiochem, San Diego, CA). Apoptosis was examined further with an in situ TUNEL assay on HCC-LM3-fLuc xenografted tumor tissues (TUNEL, QIA39). Apoptotic HCC-LM3-fLuc cells labeled with fluorescein dye were examined under the fluorescence microscope (Leica DFC450C). Three sections of each group were immunostained, and five fields for each section were chosen randomly for counting the apoptotic cells and proliferation cells [49, 50] . Tumor micro-vessel density (MVD) was quantified by two investigators independently in a blinded manner according to the method reported previously using sections immunostained with CD31 (BioLegend, San Diego, CA) [51] . Micro-vessel counting was performed on three separate fields of each section (three sections per mouse) chosen randomly at 200Â magnification. Each stained endothelial cell or cell cluster was counted as one micro-vessel. Two or more continuous CD31-positive foci in space were also counted as one micro-vessel. The average number of vessels of these fields in three sections was counted for MVD scoring.
Statistical analysis
Quantitative data were expressed as mean ± SD. Results of two groups were compared using one-way analysis of variance (ANOVA) and a Student t-test, and p values <0.05 were believed to be statistically significant. In addition, one-way ANOVA with Dunnett's post-test was used to compare cell survival and tumor growth among three or more groups.
Results
Nanoparticle preparation and characterizations
The Au-SM5-1 NPs were prepared using methods previously reported [34] . Our methods resulted in desirable characteristics where 29.7% ± 0.49% (n ¼ 3) SM5-1 conjugation efficiency was achieved. The Au-SM5-1 NPs had a negatively charged surface with a zeta potential of about À30.14 mV and had an average diameter of 8.5 nm as measured by 90Plus/BI-MAS DLS analyzer. In addition, according to the mass of each 5 nm gold nanoparticle and drug loading efficiency [52] , about 3 SM5-1 molecules were found to be conjugated with one gold nanoparticle. Au-SM5-1 NPs, Au-IgG NPs and Au NPs were examined by TEM and they were found to be spherical, shown in Fig. 1A 
In vitro proliferation assay and toxicity studies
The cytotoxic activity of various drugs tested on HCC-LM3-fLuc and HepG2 cell lines were determined ( Fig. 2A and B) . To validate the toxicity of Au NPs, SM5-1, IgG, Au-IgG NPs and Au-SM5-1 NPs, four organs including heart, liver, spleen, and kidney of the mice were sectioned on the 17th day post-treatment and stained with H&E. The results showed no obvious toxicity effects of Au-SM5-1 NPs in all organs (Fig. 2D) . Similarly, no obvious toxicity effects in the four organs were observed in Au NPs, IgG, SM5-1 and Au-IgG NPs treated group (not shown).
Cell uptake
For Au-SM5-1 NPs and SM5-1, cell uptake efficiency was defined as the percentage of SM5-1-FITC amount in the cells versus the total amount of cells. As the mass of Au NPs can be characterized according to the size of the nanoparticles [52] , we could obtain the number of nanoparticles per cell derived from the results of the ICP-MS and calculated the uptake efficiency, shown in Fig. 3 . Generally speaking, endocytosis pathways contain macropinocytosis, clathrin-dependent endocytosis, caveolin-dependent pathways. Thus, internalization pathways of Au-SM5-1 NPs, Au NPs and SM5-1 could be investigated with specific endocytosis inhibitors including sodium azide, b-cycloamylose, amiloride and the results were shown in Fig. 3 . For Au-SM5-1 NPs group, sodium azide, b-cycloamylose and amiloride can inhibit 39.3%, 11.8% and 22.5% cell uptake per cell respectively (Fig. 3D) . For Au NPs group, the inhibitory rates of sodium azide, b-cycloamylose and amiloride are 29.2%, 8.3%, 6.3% respectively (Fig. 3E) . For antibody SM5-1, all the three endocytosis pathways are not obvious (Fig. 3C ). As shown in Fig. 3DeF , more Au-SM5-1 NPs could be enclosed into the cells contrast with Au NPs and antibody SM5-1 without inhibition agents. According to Fig. 3D and F, the average uptake of SM5-1 per cell in FITC-Au-SM5-1 is 534 and that in FITC-SM5-1 is 54, so the uptake fold is 9.89 between these two drugs which is the cause of different antitumor efficacy of the two drug.
High DUOX2 expression associated with cell apoptosis
Using the complementary DNA microarray chip, a large-scale analysis of gene expression was performed during SM5-1 treatment. Target genes, which either up-or down-regulated more than two-fold at one or more time points, were selected (p < 0.05). Among the significantly changed genes in DNA microarray experiment (S.1) DUOX2, NOX1 (common genes which cause cell apoptosis for antitumor drugs) are obviously down-regulated genes which can change the oxidase gene expression level and disturb the dynamic balance of ROS enzyme system and this phenomenon was verified by qRT-PCR [53e55].
In addition, as an important negative regulatory factor of cell cycle, gene P21 was up-regulated that was verified by qRT-PCR too. Fig. 4 clearly showed that genes DUOX2 and NOX1 were downregulated and gene P21 was up-regulated obviously in contrast to the other three groups.
Au-SM5-1 NPs induces cell cycle arrest at the G1 checkpoint
To further study Au-SM5-1 NPs -induced cell growth inhibition, changes in cell cycle progression were monitored using a flow cytometric analysis. As shown in Fig. 5 , it was found that 67.2% of cells were distributed in the G1 phase after Au-SM5-1 treatment and 54.7% of cells stayed in the G1 phase after the PBS treatment (p < 0.05). To a certain degree, Au-SM5-1 NPs led to a decrease in cell numbers in S phase and G2/M phase. However, SM5-1 and Au NPs had less influence on cell cycle distribution. All these results indicated that Au-SM5-1 NPs induced cell arrest at the G1 
In vivo antitumor study based on a subcutaneous liver tumor
To evaluate antitumor activities of different drugs, HCC-LM3-fLuc cells were implanted subcutaneously into mice. The therapy study was initiated after the tumor size grew to about 50 mm 3 by
injecting Au-SM5-1 NPs (high and low), Au-IgG NPs, IgG, Au NPs, SM5-1, or PBS through the tail veins. Tumor-bearing mice were treated with four doses administered sequentially on day 0, 1, 2, and 3. For Au-SM5-1 NPs (high) group, another four doses were administered sequentially on day 12, 13, 14, 15. The tumor sizes of nude mice were then measured with calipers. As shown in Fig. 6 , the tumor sizes increased continuously in six treatment groups at the duration of the experiment. Notably, on day 12, the tumor sizes in the Au-SM5-1 NPs (low) treatment group were significantly smaller (p < 0.01) than those in the Au-IgG NPs, IgG, Au NPs, SM5-1, and PBS groups, and the maximum inhibition rates for treatment groups were 43.78% ± 3.45%, 13.55% ± 3.15%, 10.33% þ 2.12%,12.00% ± 3.12%, and 16.78% ± 2.36%, respectively. Afterward, the tumor size difference between the Au-SM5-1 NPs (low) treated group and the PBS treated group gradually reduced, however, the tumor sizes of Au-SM5-1 NPs (high) treated group were obviously smaller than the other five groups. On day 30, the inhibition rate was 49.70% for the Au-SM5-1 NPs (high) treated group but only 18.80% (p < 0.01) for the Au-SM5-1 NPs (low) treated group.
The baseline BLI signal was also determined on the day before the first drug administration, and then BLI was performed on day 0, 6, 12, 18, 24, and 30 to monitor the tumor growth of the HCC-LM3-fLuc tumor. The bioluminescent image of HCC-LM3-fLuc cells in the right flank was acquired at the 8th minute after the intraperitoneal injection with 200 ml of D-Luciferin (shown in Supplementary   Fig. 4 ). The tumor size was continuously increasing for PBS, Au NPs, and SM5-1, IgG, Au-IgG NPs groups, and only a small amount of inhibition was observed in the Au NPs and SM5-1 treated groups. As expected, the treatment with Au-SM5-1 NPs (low and high) clearly showed that the tumor growth rate decreased significantly in vivo on day 12. As determined by BLI, it was found that the bioluminescent intensity of the Au-SM5-1 NPs (low and high) treated group was the weakest on the 12th day after drug administration in contrast to the other three groups. Au-SM5-1 NPs induced a 40.10% ± 4.34%, 31.37% ± 5.12%, and 30.63% ± 4.87% tumor growth inhibition rate on day 12, 18, and 24 post-treatment, respectively. After that, the bioluminescent intensity of the Au-SM5-1 NPs (low) treatment group was similar to the other (day 0, 1, 2, 3) . (D) The correlation of bioluminescent intensity and tumor volume of the five groups (**p <0.01, mean ± SD, n¼5).
groups. However, another round of administration of Au-SM5-1 NPs sustained the inhibition efficacy on tumor and the final inhibition rate was 57.6% at day 30. The antitumor efficacy determined by BLI was consistent with caliper measurements of tumor sizes, shown in Fig. 6 .
Throughout the antitumor study, the weights of Au-SM5-1 NPs (high), Au-SM5-1 NPs (low), SM5-1, Au-IgG NPs, IgG, Au NPs, and PBS-treated mice were monitored (Fig. 6D) . None of the animals in the Au-SM5-1 NPs (high and low) treated groups show significant difference from the mice in the other five groups.
In vivo antitumor study based on orthotopic liver tumor models
The bioluminescent intensity of each mice could be calculated using our developed software Windows Molecular Imaging System (WINMI) [40] and the bioluminescent images of Au-SM5-1 NPs group and Au-IgG NPs group on 30th day were shown in Fig. 7A which indicate that Au-SM5-1 NPs can obviously inhibit the tumor growth than Au-IgG NPs. For Au-SM5-1 NPs group, BLI signals of the mice increased more slowly and became significantly different from the other five groups from day 12 post-treatment (shown in Fig. 7E ). There was no obvious difference in BLI signals of the mice between Au NPs, SM5-1, IgG, Au-IgG NPs and PBS group. According to calculated BLI signal intensity of the mice abdomen determined by formula (2), the tumor inhibition rates of Au-SM5-1 NPs, Au-IgG NPs, IgG, Au NPs, SM5-1 were 38.03% ± 4.35%, 4.77% ± 1.46%, 8.37% ± 1.37%, 6.42% ± 1.05%, 9.39% ± 1.18% respectively on day 30, shown in Fig. 7F .
In order to further analyze the antitumor efficacy, BLT method combined micro-computer tomography technology (CT) was used to reconstruct 3D information of the inner bioluminescence source. In the process of the reconstruction program, the threshold was adjusted as 0.65 and the regularization was set to i Â 10 2, 3, 4, 5, 6, 7, 8, 9) . The reconstruction results of Au-SM5-1 NPs and Au-IgG NPs based on heterogeneous mice are shown in Fig. 7B . As there are not obvious differences between Au-IgG NPs and Au NPs, SM5-1, IgG, the reconstruction results of the behind three groups were not shown in this paper. In order to show the difference clearly, three planes of the tumor including transverse slice, coronal slice and sagittal slice were isolated from the 3D reconstructed data, as shown in Fig. 7C and D. After 3D reconstruction, we calculated the volume of bioluminescence source of tumor-bearing mice in each group, the data was shown in Table 2 . The results showed that the inhibition rates of Au-SM5-1 NPs, AuIgG NPs, IgG, SM5-1, Au NPs were 39.64% ± 4.87%, 7.98% ± 2.79%, 7.54% ± 2.23%, 6.98% ± 3.12%, 7.56% ± 2.76% respectively. As listed at the second column in Table 2 , the reconstructed tumor volumes were coincident with the results determined by the abdomen bioluminescence intensity of orthotopic liver tumor mice.
The effect of Au-SM5-1 on tumor angiogenesis, apoptosis, and proliferation
The above study suggested that Au-SM5-1 NPs inhibited tumor proliferation and induced tumor cell apoptosis. For further verification of these results, xenografts of HCC-LM3-fLuc tumor tissues from PBS, Au NPs, SM5-1, IgG, Au-IgG NPs and Au-SM5-1 NPs on mice were sliced and stained using the TUNEL assay and KI67 assay and examined with a fluorescence microscope (results are shown in Fig. 8 ). From Fig. 8AeF , the number of apoptotic nuclei (green (in the web version)) was smaller in Au NPs-, SM5-1-, Au-IgG NPs-, IgG-and PBS-treated xenografts compared to those in Au-SM5-1 NPs-treated xenografts. Fig. 8GeL showed that the inhibitory effects of Au-SM5-1 NPs on tumor growth were consistent with the results of the apoptosis study as revealed by the TUNEL assay. Angiogenesis is a prerequisite for advanced tumor growth, and thus, the number of vessels per field was counted to evaluate the anti-angiogenesis efficacy of the drugs (Fig. 8MeR) .The quantitative results (Fig. 8M, N) showed that the antitumor activity of Au-SM5-1 NPs was 40% more effective than PBS. The results showed that Au-SM5-1 NPs had higher efficacy to down-regulate tumor angiogenesis than those of the other three groups (Fig. 8SeU) . The antitumor efficacy of Au NPs and SM5-1 was far worse than Au-SM5-1 NPs treated group because of the lower accumulation of Au NP and SM5-1 compared to Au-SM5-1 NPs. Similarly, Au-IgG NPs and IgG can hardly inhibit the tumor growth too. Thus, all these data demonstrated that Au-SM5-1 NPs had the highest antitumor efficacy, whereas the antitumor efficacies of Au NPs, AuIgG NPs, IgG and SM5-1 groups were a bit higher to the PBS treated group.
Discussion
HCC is a type of liver cancer found in the world with a high incidence and high death rate [1, 2] . Previous studies have shown that SM5-1 can inhibit Ch-Hep-3 tumor cell proliferation [18] . Here, we prepared SM5-1-conjugated Au NPs and investigated their enhanced efficacy of cell proliferation inhibition in the HCC-LM3 cells and tumor reduction in xenograft nude mouse model. Au-SM5-1 NPs showed improved antitumor efficacy compared with untreated and SM5-1 alone both in vitro and in vivo, this may be achieved through the following biological characteristics.
First of all, passive transport function of Au NPs delivered Au-SM5-1 NPs to surrounding of the tumor cells with diminished immune clearance [27] . This may due to lackness of a thymus for nude mice. They cannot generate mature T lymphocytes. Therefore they are unable to mount adaptive immune responses [16] . Another reason for this passive transportation may be that the targeted nanoparticles are designed to bind to SM5-1 binding protein on HCC cells, thus possible delaying clearance from the site of the tumor [14] . Sodium azide, b-cycloamylose and amiloride are the inhibitory agent of clathrin-dependent endocytosis, macropinocytosis endocytosis and caveolin-dependent pathways respectively. For Au-SM5-1 NPs group, sodium azide, b-cycloamylose and amiloride can inhibit 39.3%, 11.8% and 22.5% cell uptake respectively. The results proved that enhanced clathrin- Table 2 Reconstruction results of the six groups using the finite element method based on bioluminescent intensity calibration.
Group
Reconstructed dependent endocytosis as well as the binding affinity of antibodyreceptor increased the concentration of Au-SM5-1 NPs which resulted in improving anti-proliferative effect [56] . In addition, Au NPs can prolong the retention time of the drugs in the tumor. This will increase the probability of endocytosis, resulting in an increased cell proliferation inhibition rate. After endocytosis, Au-SM5-1 NPs obviously inhibited the cell proliferation and induced cell apoptosis through regulating some genes. To study the mechanisms, Genechip technology has been used to identify associated genes and to evaluate their expression levels under various conditions [57e63]. Then, bioinformatics was employed to analyze functions and pathways of differential expression genes. Down-regulated DUOX2 and NOX1 can change the oxidase gene expression level and disturb the dynamic balance of reactive oxygen species (ROS) enzyme system. They further inhibit tumor cell proliferation and induce cell apoptosis [53, 55] . As an important negative regulatory factor of cell cycle, gene P21 influence the activity of cyclin-dependent kinase (CDK) through competitively binding cyclin B and cyclin E and further influence the progress of cell cycle. While the up-regulation of P21 would lead to cell cycle arrested at G 1 /S or G 2 /S.
Additionally, Au-SM5-1 NPs may be accumulated to the tumor and subsequently inhibits angiogenic which plays a key role in tumor formation. This effect was examined via bioluminescence imaging in subcutaneous and orthotopic liver tumor model [38e41,64e69]. Our results indicated that Au-SM5-1 NPs can significantly inhibit tumor growth in xenograft mouse model.
In summary, we demonstrated the synthesis and characterization of SM5-1-conjugated Au NPs for immunotherapy of hepatocellular carcinoma. The results indicated that Au-SM5-1 NPs could efficiently inhibit cell proliferation and induce cell apoptosis in HCC-LM3 cells compared with SM5-1 alone both in vitro and in vivo. It is believed that the conjugation of SM5-1 to Au NPs provides a potential approach for target therapy of p230 over-expressed cancer, such as hepatocellular carcinoma, melanoma and breast cancer.
Conclusion
In this study, SM5-1 conjugated Au NPs have been successfully prepared and applied in the treatment of HCC. Both in vitro and in vivo results demonstrated that conjugation of SM5-1 and Au NPs efficiently increased the tumor growth inhibition rates in HCC which overexpressed a membrane protein (p230) with 230-kDa. In addition, we investigated the tumor growth inhibition efficacy of Au-SM5-1 NPs for orthotopic liver tumor treatment. The reconstruction results of 3D information of the inner bioluminescence source showed that Au-SM5-1 NPs can achieve considerable antitumor efficacy in HCC. In conclusion, our results indicated that Au NPs conjugated SM5-1 antibody provided a potential therapy approach for HCC targeted therapy.
